Tarveda Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Watertownmassachusettsfounded In 2011The Company Specializes In Developing Precision Oncology Medicinesparticularly Through Its Proprietary Pentarinatechnologythis Technology Focuses On Creating Miniature Drug Conjugates That Target Solid Tumorsaiming To Enhance Treatment Efficacy While Reducing Side Effects The Company S Lead Drug Candidatepen 866Targets The Activated Form Of Heat Shock Protein 90Hsp90And Is Currently In Phase 2A Trials For Various Solid Tumorsother Notable Products Include Pen 221Which Targets Tubulin For Advanced Cancersand T 2143Which Is Still In Development And Targets Hsp90 And Pi3Ks In Solid Tumorstarveda Therapeutics Collaborates With Other Pharmaceutical Entities To Advance Its Innovative Cancer Therapies
